Patent ID: 8501906
Filing Date: 2013-08-06
Classification: A61K,A61P,C07K

Abstract:
1. A compound for treating cancer comprising: an anti-cancer chemotherapeutic agent linked to an insulin-like growth factor-1 (IGF-1) receptor ligand; wherein the IGF-1 receptor ligand is a variant IGF-1 that has reduced binding affinity for soluble IGF-1 binding proteins compared to wild-type IGF-1 wherein the variant IGF-1 comprises the polypeptide structure A A A A A A A A A A R provided the variant IGF-1 does not consist of SEQ ID NO:1; wherein the variant IGF-1 does not comprise SEQ ID NO:11; wherein the variant IGF-1 comprises SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO:17.